•
Jun 30, 2022
RAPT Q2 2022 Earnings Report
RAPT Therapeutics reported financial results for the second quarter of 2022 and maintained a strong cash position.
Key Takeaways
RAPT Therapeutics reported a net loss of $19.2 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $207.3 million as of June 30, 2022.
Initiated Phase 2b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis.
Strengthened balance sheet with a $50 million financing.
Expect to broaden the RPT193 program with the initiation of a Phase 2a trial in asthma.
Continue advancing FLX475 program in multiple cancer indications.